Implications of Contact Days in the Treatment of Relapsed Refractory Diffuse Large B-Cell Lymphoma

被引：0
|
作者：
Bojanini, Leyla [1 ]
Gupta, Neel [1 ]
Khaki, Ali Raza [1 ,2 ]
机构：
[1] Stanford Univ, Dept Med, Div Oncol, Stanford, CA USA
[2] Stanford Univ, Dept Med, Div Oncol, Stanford, CA 94305 USA
来源：
ONCOLOGIST | 2023年 / 28卷 / 09期
关键词：
D O I：
10.1093/oncolo/oyad204
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：750 / 751
页数：2
相关论文
共 50 条
  • [1] Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Friedberg, Jonathan W.
    HEMATOLOGY-AMERICAN SOCIETY HEMATOLOGY EDUCATION PROGRAM, 2011, : 498 - 505
  • [2] Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma
    Salles, Gilles
    Dlugosz-Danecka, Monika
    Ghesquieres, Herve
    Jurczak, Wojciech
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (04) : 455 - 463
  • [3] Loncastuximab Tesirine in the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Juarez-Salcedo, Luis Miguel
    Nimkar, Santosh
    Corazon, Ana Maria
    Dalia, Samir
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (14)
  • [4] Tafasitamab for refractory/relapsed diffuse large B-cell lymphoma
    Lu, Q.
    Huang, H.
    Tang, S.
    Wang, Y.
    Yang, D-H
    DRUGS OF TODAY, 2021, 57 (09) : 571 - 580
  • [5] Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Dickinson, Michael J.
    Carlo-Stella, Carmelo
    Morschhauser, Franck
    Bachy, Emmanuel
    Corradini, Paolo
    Iacoboni, Gloria
    Khan, Cyrus
    Wrobel, Tomasz
    Offner, Fritz
    Wu, Shang-Ju
    Cartron, Guillaume
    Hertzberg, Mark
    Sureda, Anna
    Perez-Callejo, David
    Lundberg, Linda
    Relf, James
    Dixon, Mark
    Clark, Emma
    Humphrey, Kathryn
    Hutchings, Martin
    Trney, Marek
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (24): : 2220 - 2231
  • [6] Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma
    Malecek, Mary-Kate
    Watkins, Marcus P.
    Bartlett, Nancy L.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (07) : 831 - 839
  • [7] Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?
    Mondello, Patrizia
    Steiner, Normann
    Willenbacher, Wolfgang
    Ferrero, Simone
    Ghione, Paola
    Marabese, Alessandra
    Pitini, Vincenzo
    Cuzzocrea, Salvatore
    Mian, Michael
    ONCOLOGIST, 2016, 21 (09): : 1107 - 1112
  • [8] Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma: New Approved Options
    Garcia-Sancho, Alejandro Martin
    Cabero, Almudena
    Gutierrez, Norma C.
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (01)
  • [9] New and emerging therapies for the treatment of relapsed/refractory diffuse large B-cell lymphoma
    Moore, Donald C.
    Peery, Matthew R.
    Tobon, Katherine A.
    Raheem, Farah
    Hwang, Grace S.
    Alhennawi, Lin
    Hughes, Mitchell E.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (08) : 1848 - 1858
  • [10] Polatuzumab vedotin in relapsed/refractory diffuse large B-cell lymphoma
    Dietliker, N.
    Kiesel, H.
    Mueller, R.
    Mueller, A. M.
    Manz, M. G.
    Zenz, T.
    Rosler, W.
    SWISS MEDICAL WEEKLY, 2020, : 21S - 21S
12345